Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain. METHODS: of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes). RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo. CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effects of semaglutide on albuminuria and eGFR observed in the present STEP analysis are consistent with post hoc analyses of other GLP-1RA clinical trials.”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [270]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 1.8 years, efpeglenatide therapy reduced the risk of incident major adverse cardiovascular events by 27% and of a composite renal outcome event by 32%.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Self-citationType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Cited by
Items 501–600 of 873
Pattern of semaglutide prescription in a real-world Canadian patient cohort
Farahvash, A., Lee, M. C. M., Jain, R., & Jaakkimainen, L. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.06.006 · Cited by 5
Yehualashet, E., Mazroua, M. S., Narvaez, E., Jarosinski, M. C., Liang, N. L., Madigan, M. C., Chaer, R. A., & Sridharan, N. D. (2025) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2025.08.013 · Cited by 5
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Yao, Q., Liu, H., Wang, X., Zhang, Z., Xie, H., Xie, C., & Gao, H. (2026) · Biological Research · doi:10.1186/s40659-025-00665-8 · Cited by 6
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 7
Zawadka, M., Taguiam, E., Lê, M., Sanjanwala, R., Liu, S., Shah, A. H., & Kunutsor, S. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70411 · Cited by 6
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Forzano, I., Narciso, V., Canonico, M. E., Castiello, D. S., Florimonte, D., Manzi, L., Semplice, F., Vallone, D. M., Cristiano, S., Spinelli, A. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031108 · Cited by 5
Molecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease
Hu, S., Lee, K., He, C., & Fan, Y. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001053 · Cited by 5
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Implementation of Cardiometabolic Centers and Training Programs
Taha, M. B., Rao, N., Vaduganathan, M., Cainzos‐Achirica, M., Nasir, K., & Patel, K. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01459-y · Cited by 5
Xie, Y., Kuang, J., Li, Q., Hong, T., Ji, L., Kong, Y., Duan, Y., & Chen, L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069080 · Cited by 5
Zhang, C., Ma, X., Lin, W., Xu, Q., Li, H., Xu, C., Hao, M., & Kuang, H. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14109 · Cited by 5
Klein, K. R., Abrahamsen, T. J., Kahkoska, A. R., Alexander, G. C., Chute, C. G., Haendel, M. A., Hong, S., Mehta, H. B., Moffitt, R. A., Stürmer, T., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01562-1 · Cited by 5
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists
Guevara, L. R. H., Beam, W. B., & Pasternak, J. J. (2024) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000985 · Cited by 5
Joshi, N., Qasim, M. Z., Kanumilli, S., Shaukat, F., Kumar, A., Mahek, F., Khalid, S., Zeeshan, M., Shaik, M. Y., Nishat, S. M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002494 · Cited by 6
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
Hansrivijit, P., Tesfaye, H., Wexler, D. J., Abdi, R., Patorno, E., & Paik, J. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020651 · Cited by 5
Velasco, M. Á. P., Bernal-López, M. R., Trenas, A., Ricci, M., Lopez-Carmona, M. D., de Lucas, M.-D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107019 · Cited by 5
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs
McGuire, D. K., & Pagidipati, N. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00212-6 · Cited by 5
Patoulias, D., Papadopoulos, C. E., Kassimis, G., Karagiannis, A. I., & Doumas, M. N. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.08.009 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Chronic Kidney Disease—Part 1: Evaluation & Risk Assessment in CKD, Methods to Delay CKD Progression
Larsen, D., Varanasi, L., & Estrella, M. M. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.07.004 · Cited by 5
Roig, M. B., Melis, G. G., Posch, M., & König, F. (2022) · Biostatistics · doi:10.1093/biostatistics/kxac040 · Cited by 6
Evans, M., Berry, S., Nazeri, A., Malkin, S. J. P., Ashley, D., Hunt, B., & Bain, S. C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14917 · Cited by 5
Eliasson, B., Ekelund, J., Holmberg, C. N., Wolden, M. L., Matthiessen, K. S., & James, S. K. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac308 · Cited by 5
Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
Bilal, A., & Pratley, R. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.010 · Cited by 5
Self-citationMuller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
Potential cardiorenal benefits of efpeglenatide in diabetes
Ma, J., & Cooper, M. E. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00475-7 · Cited by 5
Shi, S., Li, X., Chen, Y., Li, J., & Dai, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70044 · Cited by 5
Cardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Kallash, M., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000970 · Cited by 4
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Checa-Ros, A., Okojie, O., Wassouf, J. G., Yedean, A., Hsueh, W.-C., Hebda, P., Llobell, E. R., Muhmenthaler, G. B., Tran, M. D.-D., & D’Marco, L. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020097 · Cited by 6
Vardhan, S., Arnott, C. G., Chen, A., Frolova, A. I., Meka, R. A., Raghuraman, N., Vijay, A., Yoo, S. G., & Mahmoud, Z. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101471 · Cited by 4
Rico-Fontalvo, J. E., Daza-Arnedo, R., Elbert, A. E., Correa‐Rotter, R., Diná-Batlle, E., Lorca, E., de Moraes, T. P., Sánchez-Polo, V., & Builes-Montaño, C. E. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01854-8 · Cited by 6
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
Peter, K., Roka, O., Sepp, E., Warburton, M., Zhang, J., & Cork, S. C. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00295-3 · Cited by 5
Ahmed, M., Hashmi, T. M., Shahzad, M., Zia, R., Ashraf, H., Ahmed, R., Rashid, M. O., Greene, S. J., Mentz, R. J., Fudim, M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag079 · Cited by 4
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Kahles, F., Rau, M., Reugels, M., Foldenauer, A. C., Mertens, R. W., Arrivas, M. C., Schröder, J. H., Idel, P., Moellmann, J., van der Vorst, E. P. C., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01454-3 · Cited by 5
Hösli, P., Renström, F., Laimer, M. W., Cavelti‐Weder, C., Gastaldi, G., Lehmann, R., & Brändle, M. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004108 · Cited by 4
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Abdelrahman, A. M., Awad, A. S., Hasan, I., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247732 · Cited by 4
Management of Diabetes in Patients with Chronic Kidney Disease
Ambalavanan, J., & Caramori, M. L. (2025) · Endocrine Research · doi:10.1080/07435800.2025.2473896 · Cited by 5
Gut immune cells—A novel therapeutical target for cardiovascular disease?
Ganesh, N., van der Vorst, E. P. C., Spießhöfer, J., He, S., Burgmaier, M., Findeisen, H. M., Lehrke, M., Świrski, F. K., Marx, N., & Kahles, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.943214 · Cited by 4
GLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion
Li, Z., Yu, Y., Li, J., Jiang, X., Chen, J., Ye, N., Wu, B., Sun, Y., & Sun, G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70004 · Cited by 5
GLP-1 receptor agonists—another promising therapy for Alport syndrome?
Boeckhaus, J., Mabillard, H. R., & Sayer, J. A. (2025) · Journal of Rare Diseases · doi:10.1007/s44162-024-00065-8 · Cited by 4
Batista, J. L., Makuvire, T. T., Davis, J. D., & Carbone, S. (2025) · US Cardiology Review · doi:10.15420/usc.2024.44 · Cited by 4
Narcisse, D. I., Katzenberger, D. R., & Gutierrez, J. A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01677-6 · Cited by 4
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky, B. M., Cummings, D. M., & Powell, J. R. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.03.012 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Goldenberg, R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108285 · Cited by 4
Zhang, J., Spall, H. G. C. V., Li, L., Khan, M. S., Pandey, A., Thabane, L., Bai, X., Wang, Y., Lip, G. Y. H., & Li, G. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102804 · Cited by 4
Combination therapy with kidney protective therapies: optimizing the benefits?
Kotwal, S. S., Perkovic, E., & Perkovic, V. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000929 · Cited by 4
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 4
Kimura, T., Kubo, M., Takahashi, K., Wamata, R., Iwamoto, Y., Iwamoto, H., Katakura, Y., Sanada, J., Fushimi, Y., Shimoda, M., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5880589 · Cited by 4
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
Wang, S., Frederich, R. C., & Mancuso, J. P. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-023-00575-5 · Cited by 3
Prato, S. D., Li, Z., Ramasundarahettige, C. F., Branch, K. R., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., Sattar, N. A., & Gerstein, H. C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02432-7 · Cited by 3
Self-citationTrillini, M., Jenssen, T. G., Martin, W. P., & Morales, E. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf008 · Cited by 5
Yang, T., Xue, Y., Ren, J., Li, X., Xu, W., Nie, G., Wang, D., & Wang, X. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128390373250507062606 · Cited by 3
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
Galindo, R. J., Lee, C. J., Allen, S. E., Dib, A., Boye, K. S., Thieu, V. T., Dong, W., Sapin, H., & Wiese, R. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16620 · Cited by 3
Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists
Tran-Duc, P. N., & Heo, K. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e9 · Cited by 4
Rao, Y., Meng, S., Yu, E. Y.-W., Chen, Y., van Alebeek, R., Al-Zalabani, A. H., Zeegers, M. P., & Wesselius, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.017 · Cited by 4
Yu, Z., Gu, B., Zhang, J., Jin, W., Wan, H., & Jin, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1721311 · Cited by 3
Therapeutic Advances in the Management of Cardiogenic Shock
Filipescu, R., Collins, S. P., Radu, R. I., Gal, T. B., Antohi, E., Abdelhamid, M., Geavlete, O. D., Pană, M.-A., Farmakis, D. T., Matei, D.-C., et al. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002025 · Cited by 3
Verma, S., Katwal, S., Akula, H. R., Inamdar, A., Kundukulam, S. S., Khan, M., Satti, A. B. A. Q., Menon, S., & Rai, M. (2026) · Cureus · doi:10.7759/cureus.101867 · Cited by 4
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Self-citationMahmoud, A., Sheashaa, H., Killian, M., Awad, K., Ibrahim, R., Mahmoud, A., Farina, J., Abdelnabi, M., Kamel, I., Horn, B., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134588 · Cited by 3
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Kammer, M., Heinzel, A., Hu, K., Meiselbach, H., Gregorich, M., Busch, M., Duffin, K. L., Gomez, M. F., Eckardt, K., & Oberbauer, R. W. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01808-5 · Cited by 3
Rossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3
Advancing Heart Failure Care: Breakthroughs and Emerging Strategies
Tedeschi, A., Barocelli, F., Gerra, L., Breviario, F., Palazzini, M., Conti, N., Ferraro, S., Bolognesi, M. G., Spigno, F. D., Gentile, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207253 · Cited by 5
Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
Salman, L. H., Martinez, L., Faddoul, G., Manning, C., Ali, K., Salman, M., & Vázquez-Padrón, R. I. (2023) · Kidney360 · doi:10.34067/kid.0000000000000126 · Cited by 3
Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Koh, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0096 · Cited by 3
Lalic, N. M., Jotić, A., Lukić, L., Milicic, T. J., Macesic, M. V., Gajović, J. S., Stoiljkovic, M. M., Milovancevic, M. M., Cvetković, D. R., & Lalic, K. S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111816 · Cited by 3
Perioperative Considerations for Patients on GLP1 Agonists
VanderWielen, B. A., & Beam, W. B. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.002 · Cited by 3
Alghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Müller‐Wieland, D., Brandts, J., Verket, M., Marx, N., & Schütt, K. S. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_537 · Cited by 4
Abdelhaleem, I. A., Abd‐Elhamied, M. A., Morsi, A. E., & Kenawy, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14602 · Cited by 3
Médicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Risk stratification of patients with INOCA: is perfusion PET imaging the game winner?
Liga, R., & Gimelli, A. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-03169-0 · Cited by 3
Santos‐Pardo, I., Witt, N., Angerås, O., & Nyström, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02071-4 · Cited by 2
Fernandez, M. L. O., Torrigiani, G., Molteni, M., Fortino, I., Cimminiello, C., & Baviera, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02674-9 · Cited by 3
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., Udell, J. A., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.010 · Cited by 2
Ghosal, S., & Ghosal, A. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s575790 · Cited by 2
Alshaikh, A., Alshehri, A., Alzubaidi, L. M. Y., Elbadawi, H., Alsaeed, A. H., Almehthel, M. S., Aldahash, R., Alsabaan, F., Alotaibi, M. S., Alghamdi, K. A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01826-4 · Cited by 2
Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes
Choi, S., Seo, J., Park, S., Kim, N. Y., Kim, H., & Lim, H.-S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1715585 · Cited by 2
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
Jaiswal, V., Mashkoor, Y., Borra, V., Gera, A., Patel, N., Jitta, S. R., NASIR, Y. M., Sharma, P., & Mattumpuram, J. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45797 · Cited by 2
Ternhamar, T., Johansen, M. Ø., Nordestgaard, B. G., & Afzal, S. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag085 · Cited by 2
Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis
Wu, Z., He, Y., Deng, H., Tan, Y., Gao, W., Yin, J., Zeng, Z., Sun, J., Zhang, L., Li, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1773015 · Cited by 2
Alkhezi, O. S., Alfehaid, L., Alanezi, A., Alotaibi, M., & Alshaya, O. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1805015 · Cited by 2
Hasebe, M., Kamido, H., Su, C., Keidai, Y., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70749 · Cited by 2
Metadata
- Authors
- Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., Dyal, L., & Branch, K.
- Affiliations
- University of Pisa (IT)
- From the Population Health Research Institute, Hamilton Health Sciences (H.C.G., C.R., L.H., L.D.), and McMaster University (H.C.G.) — both in Hamilton, ON, Canada; the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (N.S.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.); National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); Sanofi, Bridgewater, NJ (N.S.K.); the Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (S.D.P.); and the Division of Cardiology, University of Washington, Seattle (K.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 896-907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177365549
- Cited by
- 829
- References
- 29
- Citations by year
- 2026: 150 · 2025: 187 · 2024: 159 · 2023: 149 · 2022: 136 · 2021: 47
- FWCI
- 91.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- efpeglenatide, type 2 diabetes, GLP-1 receptor agonists, exendin-4, major adverse cardiovascular events, cardiovascular risk, renal outcomes, renal function decline, macroalbuminuria, SGLT2 inhibitors, gastrointestinal adverse effects, non-inferiority, cardiovascular disease history, kidney disease, cardiovascular risk factors, myocardial infarction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Kidney Diseases, Male, Middle Aged, Proline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
